June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Subthreshold Micropulse Laser Treatment in Diabetic Macular Oedema
Author Affiliations & Notes
  • Aseel Hamoud Bedan
    Ashford and Saint Peter's Hospitals NHS Trust, Chertsey, Surrey, United Kingdom
  • Fani Zacharaki
    Ashford and Saint Peter's Hospitals NHS Trust, Chertsey, Surrey, United Kingdom
  • Mohamed Rashsad
    Ashford and Saint Peter's Hospitals NHS Trust, Chertsey, Surrey, United Kingdom
  • Stephen Morgan
    Ashford and Saint Peter's Hospitals NHS Trust, Chertsey, Surrey, United Kingdom
  • Francis Carr
    Ashford and Saint Peter's Hospitals NHS Trust, Chertsey, Surrey, United Kingdom
  • Footnotes
    Commercial Relationships   Aseel Hamoud Bedan None; Fani Zacharaki None; Mohamed Rashsad None; Stephen Morgan None; Francis Carr None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3805 – F0226. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Aseel Hamoud Bedan, Fani Zacharaki, Mohamed Rashsad, Stephen Morgan, Francis Carr; Subthreshold Micropulse Laser Treatment in Diabetic Macular Oedema. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3805 – F0226.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To study the effect of micropulse MP laser treatment in patients with diabetic macular oedema DMO over a three months period.

Methods : it’s a retrospective study of 80 patients with DMO, these patients are outside the treatment criteria for anti-VEGF injections, that’s to say their best corrected visual acuity BCVA is better than 6/12, and/or the central macular thickness CMT is less than 400 micrometre. We measured there BCVA, CMT before and three months after MP laser treatment. We used coloured photographs, fundus autofluorescence FAF, and optical coherent tomography OCT to highlight and marks left on the retina after treatment.

Results : At three months 43 of the patients improved their BCVA, 25 worsened. CMT showed improvement in 43 of the patients and worsened in 36. Retreatment was not done on any of them using the 3 months. No one of the patients had any laser scars or marks detected on biomicroscopy, FAF or OCT scans.

Conclusions : MP laser treatment is an effective, affordable way of treating patients with DMO not meeting the treatment criteria of anti-VEGF injections.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×